First quarter results reflect challenging revenue picture. Pipeline strengthened by Amgen collaboration, the agreement to acquire Ardea Biosciences and positive CHMP opinion for FORXIGATM (dapagliflozin) in Europe.
First quarter results 2012
Announced on Thursday 26 April 2012
- Cautionary statement regarding forward looking statements (PDF 59kb)
- Press release (PDF 233kb)
- Guide to Q1 press release formatting changes (PDF 87kb)
Downloads
- Presentation (PDF 345kb)
- David Brennan (Chief Executive Officer) script (PDF 75kb)
- Simon Lowth (Chief Financial Officer) script (PDF 114kb)